Citigroup downgraded Nevro from Neutral to Sell and set a new price target of $9.00 from $13.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | Sell → Neutral | Citigroup | |
| 8/8/2024 | Underperform → Peer Perform | Wolfe Research | |
| 8/7/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | Neutral → Underweight | JP Morgan | |
| 8/7/2024 | $13.00 → $5.50 | Equal Weight → Underweight | Wells Fargo |
| 5/22/2024 | $13.50 → $9.00 | Neutral → Sell | Citigroup |
| 2/22/2024 | Outperform → Perform | Oppenheimer | |
| 1/12/2024 | $23.00 → $20.00 | Outperform → Sector Perform | RBC Capital Mkts |
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif., Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (P
REDWOOD CITY, Calif., Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on October 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induce
REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For th
Citigroup upgraded Nevro from Sell to Neutral
Wolfe Research upgraded Nevro from Underperform to Peer Perform
JMP Securities downgraded Nevro from Mkt Outperform to Mkt Perform
S-8 - NEVRO CORP (0001444380) (Filer)
8-K - NEVRO CORP (0001444380) (Filer)
10-Q - NEVRO CORP (0001444380) (Filer)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For th
Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second-quarter 2024 financial results, revised its full-year 2024 guidance, and issued third-quarter 2024 guidance. The company also announced that it is initiating a process
REDWOOD CITY, Calif., July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For thos
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi
REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately. "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and
REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately. "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a
Truist Securities analyst Richard Newitter maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $11 to $10.
Across the recent three months, 6 analysts have shared their insights on Nevro (NYSE:NVRO), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 3 1 2 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 1 2M Ago 0 0 0 0 1 3M Ago 0 0 2 1 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.37, with a high estimate of $13.00 and a low estimate of $8.20. A negative shift in s
Morgan Stanley analyst Cecilia Furlong maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $14 to $9.